Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Agios Pharmaceuticals’ dense clinical disclosures can feel like hunting for a single mutation in a genome. R&D expenses tied to pyruvate-kinase activators, FDA feedback on sickle-cell trials, and collaboration milestone payments sprawl across hundreds of pages. If you have ever asked, “How do I read the Agios Pharmaceuticals annual report 10-K simplified?” or searched for “Agios Pharmaceuticals insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI-powered analysis turns that challenge into clarity. Our system ingests every 10-K, 10-Q, 8-K and S-1 the moment it hits EDGAR, then delivers plain-English summaries that highlight trial progress, cash runway and key risks—Agios Pharmaceuticals SEC filings explained simply. You can monitor Agios Pharmaceuticals Form 4 insider transactions real-time, receive alerts on Agios Pharmaceuticals quarterly earnings report 10-Q filing numbers, and access AI commentary that points to pivotal PK-activation data. Whether you need an Agios Pharmaceuticals earnings report filing analysis or a quick read on an Agios Pharmaceuticals 8-K material events explained, the insights are waiting.
Investors use this page to:
- Track Agios Pharmaceuticals executive stock transactions Form 4 before catalytic trial read-outs
- Compare period-over-period R&D spend without sifting through footnotes
- Review the Agios Pharmaceuticals proxy statement executive compensation for alignment with shareholder interests
- Gauge cash runway against pipeline timelines in seconds—understanding Agios Pharmaceuticals SEC documents with AI
Agios Pharmaceuticals (AGIO) Q2-25 10-Q highlights:
- Revenue: PYRUKYND® sales rose 45% YoY to $12.5 m for the quarter and 26% YoY to $21.2 m YTD.
- Losses: Operating loss widened to $233.7 m YTD (-18%) as R&D spend climbed 13% to $164.7 m and SG&A 31% to $87.4 m. Net loss YTD was $201.3 m (-$3.49/sh) vs $177.7 m (-$3.14/sh) in 2024.
- Cash runway: Cash, cash equivalents and marketable securities total $1.31 bn (-$143 m from YE-24) after $188.6 m operating cash burn; management still projects ≥12-month liquidity.
- Balance sheet: Equity fell to $1.37 bn (-11%) on growing accumulated deficit (-$350 m). No debt reported.
- Clinical & regulatory: FDA accepted sNDA for PYRUKYND in α/β-thalassemia (PDUFA 7-Sep-25); EMA and GCC filings submitted. Phase 3 ENERGIZE & ENERGIZE-T met primary/secondary endpoints but revealed hepatocellular injury risk—monthly LFT monitoring now included in label & protocols.
- Pipeline spend: $10 m milestone paid to Alnylam for TMPRSS6 siRNA (AG-236). Phase 2/3 RISE-UP for SCD ongoing.
- Outlook: Company remains pre-profit; commercialization of PYRUKYND beyond PK-deficiency and retained earn-out on vorasidenib royalties are key value drivers.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) filed an 8-K announcing the election of Jay Backstrom, M.D., MPH, to its Board of Directors. The Board approved his appointment on 3 July 2025, effective 8 July 2025, as a Class III director serving until the 2028 annual meeting.
Compensation package under the non-employee director policy:
- Annual cash retainers: $50,000 for board service and $7,500 for Science & Technology Committee duties.
- Equity awards effective 8 July 2025: (i) non-statutory stock option with a Black-Scholes grant-date value of $472,500; (ii) restricted stock units valued at $157,500. The option strike price equals the closing market price on the grant date. Vesting: 25 % of options after one year, remainder monthly over 36 months; RSUs vest one-third annually over three years.
- Standard reimbursement of reasonable travel expenses.
Dr. Backstrom will also sign the company’s standard indemnification agreement. The filing states there are no related-party transactions or other arrangements connected to his selection.
The disclosure is limited to governance matters; it does not include financial results or operational updates.
Schedule 13G filing: Bellevue Group AG and its wholly-owned subsidiary Bellevue Asset Management AG have disclosed a new beneficial ownership position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO).
- Stake size: 3,515,150 common shares, representing 6.1 % of the outstanding class as of the triggering date 06 / 01 / 2025.
- Voting & dispositive power: The reporting persons hold shared voting and dispositive power over the entire position; they report zero sole voting/dispositive power.
- Reporting entities: Bellevue Group AG (parent holding company, Switzerland) and Bellevue Asset Management AG (investment manager, Switzerland) filed jointly.
- Purpose: The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control, as certified in Item 10.
- Form details: Filed 07 / 07 / 2025 under Rule 13d-1(b); CUSIP 00847X104; security class – common stock.
This disclosure introduces Bellevue as a >5 % institutional holder in Agios. While no strategic intentions are indicated, the filing may signal incremental institutional confidence and can affect perceptions of the shareholder base composition.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
